by Stephen Levin
Patience may be regarded as a virtue, but in today's medical device environment, start-up investors have little choice but to...
Novacept: A Patient Device Exit Strategy Succeeds
Using an aggressive clinical trials strategy to overcome early setbacks, Novacept is proof a small company can succeed in a big company market, and that a patient exit strategy can pay off for device companies--evidenced by Cytyc's $325 million cash acquisition of Novacept.